DOP2017000123A - Análogos de urea unidos sustituidos como moduladores de sirtuina - Google Patents

Análogos de urea unidos sustituidos como moduladores de sirtuina

Info

Publication number
DOP2017000123A
DOP2017000123A DO2017000123A DO2017000123A DOP2017000123A DO P2017000123 A DOP2017000123 A DO P2017000123A DO 2017000123 A DO2017000123 A DO 2017000123A DO 2017000123 A DO2017000123 A DO 2017000123A DO P2017000123 A DOP2017000123 A DO P2017000123A
Authority
DO
Dominican Republic
Prior art keywords
diseases
disorders
modulators
sirtuina
united
Prior art date
Application number
DO2017000123A
Other languages
English (en)
Inventor
Michael Fox Ryan
Lamond Ellis James
Anderson Evans Karen
Henry Miller William
Andrew Seefeld Mark
Original Assignee
Glaxosmithkline Intellectual Property (No 2) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property (No 2) Ltd filed Critical Glaxosmithkline Intellectual Property (No 2) Ltd
Publication of DOP2017000123A publication Critical patent/DOP2017000123A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos compuestos análogos de urea unidos sustituidos de Fórmula (I) o sales farmacéuticamente aceptables de los mismos, composiciones farmacéuticas correspondientes, procesos para preparar y usar dichos compuestos, solos o en combinación con otros agentes terapéuticos, como Moduladores de Sirtuina útiles para aumentar la longevidad de una célula, y en el tratamiento y/o la prevención de una amplia diversidad de enfermedades y trastornos, que incluyen, pero sin limitación, por ejemplo, enfermedades o trastornos relacionados con el envejecimiento o la tensión, diabetes, obesidad, enfermedades neurodegenerativas, enfermedad cardiovascular, trastornos de la coagulación sanguínea, inflamación, cáncer y/o enrojecimiento así como enfermedades o trastornos que se beneficiarían de la actividad mitocondrial aumentada.
DO2017000123A 2014-11-19 2017-05-18 Análogos de urea unidos sustituidos como moduladores de sirtuina DOP2017000123A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462081916P 2014-11-19 2014-11-19

Publications (1)

Publication Number Publication Date
DOP2017000123A true DOP2017000123A (es) 2017-08-15

Family

ID=54705247

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000123A DOP2017000123A (es) 2014-11-19 2017-05-18 Análogos de urea unidos sustituidos como moduladores de sirtuina

Country Status (21)

Country Link
US (4) US10072011B2 (es)
EP (4) EP3221322A1 (es)
JP (4) JP2017534663A (es)
KR (4) KR20170083134A (es)
CN (4) CN107207520A (es)
AU (4) AU2015348941A1 (es)
BR (4) BR112017010599A2 (es)
CA (4) CA2968027A1 (es)
CL (1) CL2017001275A1 (es)
CO (1) CO2017004994A2 (es)
CR (1) CR20170209A (es)
DO (1) DOP2017000123A (es)
EA (1) EA201791074A1 (es)
ES (1) ES2823748T3 (es)
IL (1) IL252252A0 (es)
MX (1) MX2017006658A (es)
PE (1) PE20171257A1 (es)
PH (1) PH12017500913A1 (es)
RU (3) RU2017120858A (es)
SG (1) SG11201703824QA (es)
WO (4) WO2016079709A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086088A2 (en) 2014-11-25 2016-06-02 Northwestern University Wound healing through sirt1 overexpression
CN108329388A (zh) * 2018-01-18 2018-07-27 天津市湖滨盘古基因科学发展有限公司 一种人的沉默配型信息调节蛋白突变蛋白及其应用
CN108395436B (zh) * 2018-05-14 2021-01-12 鹤壁市人民医院 一种咪唑并吡嗪医药中间体的制备方法
CN108707150B (zh) * 2018-05-14 2021-04-16 江苏惠利生物科技有限公司 一种咪唑并吡嗪医药中间体的制备方法
CN110478339A (zh) * 2019-08-12 2019-11-22 昆明理工大学 紫铆因在制备靶向恢复突变p53构象药物中的应用
KR20220056223A (ko) * 2019-09-02 2022-05-04 메르크 파텐트 게엠베하 유기 전계발광 디바이스용 재료
CN114890955A (zh) * 2022-06-23 2022-08-12 江西瑞威尔生物科技有限公司 一种n取代吗啉类有机化合物的制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2006094210A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
US9556201B2 (en) * 2009-10-29 2017-01-31 Glaxosmithkline Llc Bicyclic pyridines and analogs as sirtuin modulators
JP2015504868A (ja) * 2011-12-12 2015-02-16 エスエムビー・イノベーション・アンパルトセルスカブＳＭＢ Ｉｎｎｏｖａｔｉｏｎ ＡｐＳ サーチュイン結合および調節に有用な新規複素環化合物
WO2014186313A1 (en) * 2013-05-13 2014-11-20 Glaxosmithkline Llc Substituted bridged urea analogs as sirtuin modulators

Also Published As

Publication number Publication date
JP6806679B2 (ja) 2021-01-06
US10072011B2 (en) 2018-09-11
KR20170087907A (ko) 2017-07-31
IL252252A0 (en) 2017-07-31
CR20170209A (es) 2017-07-17
BR112017010599A2 (pt) 2017-12-26
KR20170083135A (ko) 2017-07-17
JP2017534663A (ja) 2017-11-24
PE20171257A1 (es) 2017-08-28
EP3221317B1 (en) 2020-07-22
CA2968029A1 (en) 2016-05-26
CN107207509B (zh) 2020-04-21
EP3221316A1 (en) 2017-09-27
CA2968030A1 (en) 2016-05-26
AU2015348943A1 (en) 2017-06-01
AU2015348944A1 (en) 2017-06-01
BR112017010602A2 (pt) 2017-12-26
ES2823748T3 (es) 2021-05-10
JP2017534664A (ja) 2017-11-24
KR20170083133A (ko) 2017-07-17
RU2017120857A (ru) 2018-12-19
RU2017120858A (ru) 2018-12-19
WO2016079712A1 (en) 2016-05-26
US20180319810A1 (en) 2018-11-08
CA2968032A1 (en) 2016-05-26
MX2017006658A (es) 2018-01-15
SG11201703824QA (en) 2017-06-29
CO2017004994A2 (es) 2017-09-20
WO2016079710A1 (en) 2016-05-26
BR112017010595A2 (pt) 2018-01-02
WO2016079711A1 (en) 2016-05-26
BR112017010601A2 (pt) 2017-12-26
PH12017500913A1 (en) 2017-12-04
EP3221322A1 (en) 2017-09-27
EP3220918A1 (en) 2017-09-27
US20170355705A1 (en) 2017-12-14
CN107207509A (zh) 2017-09-26
AU2015348941A1 (en) 2017-06-01
RU2017120855A (ru) 2018-12-19
CN107207521A (zh) 2017-09-26
EP3221317A1 (en) 2017-09-27
EA201791074A1 (ru) 2017-10-31
JP2017534665A (ja) 2017-11-24
CN107108627A (zh) 2017-08-29
US20190048016A1 (en) 2019-02-14
CA2968027A1 (en) 2016-05-26
JP2017534662A (ja) 2017-11-24
KR20170083134A (ko) 2017-07-17
WO2016079709A1 (en) 2016-05-26
CN107207520A (zh) 2017-09-26
AU2015348942B2 (en) 2018-07-05
US20170362234A1 (en) 2017-12-21
AU2015348942A1 (en) 2017-06-01
CL2017001275A1 (es) 2017-12-15

Similar Documents

Publication Publication Date Title
DOP2017000123A (es) Análogos de urea unidos sustituidos como moduladores de sirtuina
UY34974A (es) Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
CO6400181A2 (es) Compuestos de tiazolopiridina moduladores de sirtuina
DOP2017000013A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
PE20151067A1 (es) Inhibidores de autotaxina
AU2014265671A8 (en) Substituted bridged urea analogs as sirtuin modulators
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
EA201171098A1 (ru) 8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина
CO6670589A2 (es) Compuestos para reducir la producción de beta-amiloide
CR20160352A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
UY35146A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CR20140554A (es) Compuestos de acido dimetil-benzoico
CR20130530A (es) Derivados glucósidos y sus usos para el tratamiento de la diabetes
CR20140553A (es) Compuestos de fenoxietil piperidina
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
UY35158A (es) ?moduladores selectivos del receptor de andrógenos novedosos?.